CYTOCARB 150MG/15ML (150MG) VIAL

Description An organoplatinum compound that possesses antineoplastic activity. Indication For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have been previously treated with cisplatin. Mechanism of action Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases preventing DNA synthesis and RNA transcription from the affected DNA 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription and 3) the induction of mispairing of the nucleotides leading to mutations.